Mellitus is developing a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk and as a clinical trial test for pharmaceutical development. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM).

Medical Devices

Mellitus

Rick Saul

Kathy Welch

Jing Shi

The Leadership Team at Mellitus is responsible for setting the strategic direction of the company and overseeing the development of its innovative in vitro diagnostic test for Glycated CD59. Comprising co-founders with a wealth of expertise, the team makes key decisions regarding product development, corporate partnerships, and navigating regulatory pathways, all aimed at advancing the company's mission to improve diabetes screening and management.

Leadership Team

About

Team members

Other teams at Mellitus

Board Members